[go: up one dir, main page]

WO2008102790A1 - 涙液の減少に伴う疾患の予防または治療用医薬組成物 - Google Patents

涙液の減少に伴う疾患の予防または治療用医薬組成物 Download PDF

Info

Publication number
WO2008102790A1
WO2008102790A1 PCT/JP2008/052814 JP2008052814W WO2008102790A1 WO 2008102790 A1 WO2008102790 A1 WO 2008102790A1 JP 2008052814 W JP2008052814 W JP 2008052814W WO 2008102790 A1 WO2008102790 A1 WO 2008102790A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atom
prevention
pharmaceutical composition
treatment
disease associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/052814
Other languages
English (en)
French (fr)
Inventor
Mamoru Kobayashi
Tetsuya Asari
Mariko Tadachi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Priority to BRPI0807715-0A priority Critical patent/BRPI0807715A2/pt
Priority to JP2009500203A priority patent/JPWO2008102790A1/ja
Priority to AU2008218028A priority patent/AU2008218028A1/en
Priority to MX2009008994A priority patent/MX2009008994A/es
Priority to EP08711620A priority patent/EP2123268A1/en
Priority to CA002677582A priority patent/CA2677582A1/en
Publication of WO2008102790A1 publication Critical patent/WO2008102790A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

【課題】　　　涙液の減少に伴う疾患の予防または治療用医薬組成物を提供する。 【解決手段】　一般式（I）： （式中のＡは低級アルキレン基であり、Ｂはアミノ基、ジ低級アルキルアミノ基または環内に酸素原子を含んでいてもよい３～７員環の脂環式アミノ基であり、＊が付された炭素原子はＲ配置またはS配置の炭素原子若しくはそれらが混合した炭素原子を示し、（Ｓ）が付された炭素原子はＳ配置の炭素原子を示す）で表されるフェニルエタノールアミノテトラリンカルボン酸アミド誘導体またはその薬理学的に許容される塩等を有効成分として含有することを特徴とする、涙液の減少に伴う疾患（ドライアイ、乾性角結膜障害、角膜上皮障害、涙液分泌減少症、眼球乾燥症、加齢乾性眼、スチーブンス－ジョンソン症候群の眼障害、シェーグレン症候群の眼障害、角結膜潰瘍、コンタクトレンズ装着時の乾燥等）の予防または治療用医薬組成物を提供する。
PCT/JP2008/052814 2007-02-21 2008-02-20 涙液の減少に伴う疾患の予防または治療用医薬組成物 Ceased WO2008102790A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0807715-0A BRPI0807715A2 (pt) 2007-02-21 2008-02-20 Composição farmacêutica para a prevenção ou o tratamento de doença associada com a redução de lacrimação.
JP2009500203A JPWO2008102790A1 (ja) 2007-02-21 2008-02-20 涙液の減少に伴う疾患の予防または治療用医薬組成物
AU2008218028A AU2008218028A1 (en) 2007-02-21 2008-02-20 Pharmaceutical composition for prevention or treatment of disease associated with tear reduction
MX2009008994A MX2009008994A (es) 2007-02-21 2008-02-20 Composicion farmaceutica para la prevencion o tratamiento de enfermedades asociadas con la reduccion de lagrimas.
EP08711620A EP2123268A1 (en) 2007-02-21 2008-02-20 Pharmaceutical composition for prevention or treatment of disease associated with tear reduction
CA002677582A CA2677582A1 (en) 2007-02-21 2008-02-20 Pharmaceutical composition for prevention or treatment of disease associated with tear reduction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-040191 2007-02-21
JP2007040191 2007-02-21

Publications (1)

Publication Number Publication Date
WO2008102790A1 true WO2008102790A1 (ja) 2008-08-28

Family

ID=39710064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052814 Ceased WO2008102790A1 (ja) 2007-02-21 2008-02-20 涙液の減少に伴う疾患の予防または治療用医薬組成物

Country Status (8)

Country Link
US (1) US20110092509A1 (ja)
EP (1) EP2123268A1 (ja)
JP (1) JPWO2008102790A1 (ja)
AU (1) AU2008218028A1 (ja)
BR (1) BRPI0807715A2 (ja)
CA (1) CA2677582A1 (ja)
MX (1) MX2009008994A (ja)
WO (1) WO2008102790A1 (ja)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038970A1 (en) 1996-04-12 1997-10-23 Kissei Pharmaceutical Co., Ltd. Phenylethanolaminotetralincarboxamide derivatives
WO2001041806A1 (en) 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
WO2007026630A1 (ja) * 2005-08-29 2007-03-08 Kissei Pharmaceutical Co., Ltd. 涙液の減少に伴う疾患の予防又は治療剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038970A1 (en) 1996-04-12 1997-10-23 Kissei Pharmaceutical Co., Ltd. Phenylethanolaminotetralincarboxamide derivatives
WO2001041806A1 (en) 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
WO2007026630A1 (ja) * 2005-08-29 2007-03-08 Kissei Pharmaceutical Co., Ltd. 涙液の減少に伴う疾患の予防又は治療剤

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Dry eye clinic", 2000, pages: 43 - 53
"Medical Aoi Publication", 1993, article "Ocular Surface no Shindan to Chiryo (Diagnosis and Treatment of Ocular Surface", pages: 15 - 30
HIROSHI H. ET AL.: "Discovery of a Novel and Potent Human and Rat beta3-Adrenergic Receptor Agonist, [3-[(2-R)-[[(2R)-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yloxy] acetic", ACID, CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 53, no. 2, 2005, pages 184 - 198, XP002424904 *
HIROSHI HARADA ET AL., CHEM. PHARM. BULL., vol. 53, 2005, pages 184 - 198
JUN SHIMAZAKI ET AL., GANKA (OPHTHALMOLOGY), vol. 37, 1995, pages 765 - 770
LEMP M.A. ET AL.: "Adler's physiology of the eye", 1992, MOSBY YEAR BOOK COMPANY, article "The lacrimal apparatus", pages: 18 - 28
MASUO AKAHANE ET AL., NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., vol. 358, 1998, pages R518
PETOUNIS A.D. ET AL., INT. OPHTHALM., vol. 13, 1989, pages 75 - 80
SULLIVAN D.A. ET AL.: "Lacrimal grand, tear film and dry eye syndromes", 1994, PLENUM PRESS COMPANY, pages: 1 - 9
TERUYUKI Y. ET AL.: "Selectivity and Potency of Agonists for the Three Subtypes of Cloned Human beta-Adrenoceptors Expressed in Chinese Hamster Ovary Cells", TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol. 192, 2000, pages 181 - 193, XP003015467 *
TERUYUKI YANAGIWSAWA ET AL., TOHOKU J. EXP. MED., vol. 192, 2000, pages 181 - 193
YOSHIFUMI H. ET AL.: "Acute and chronic effects of FR-149175, a beta3-adrenergic receptor agonists, on energy expenditure in Zucker fatty rats", AMERICAN JOURANL OF PHYSIOLOGY REGULATORY, INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, vol. 287, 2004, pages R336 - R341, XP008112433 *
YOSHIFUMI HATAKEYAMA ET AL., AM J PHYSIOL REGULATORY INTEGRATIVE COMP PHYSIOL, vol. 287, 2004, pages R336 - 341

Also Published As

Publication number Publication date
AU2008218028A1 (en) 2008-08-28
US20110092509A1 (en) 2011-04-21
MX2009008994A (es) 2009-09-03
CA2677582A1 (en) 2008-08-28
EP2123268A1 (en) 2009-11-25
JPWO2008102790A1 (ja) 2010-05-27
BRPI0807715A2 (pt) 2014-06-03

Similar Documents

Publication Publication Date Title
Sturdivant et al. Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma
WO2010004435A3 (en) Ph specific solutions of sodium mycophenolic acid for the treatment of eye disorders
US10729653B2 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
WO2007138472A3 (en) Triazolopyridazine derivatives
US20120238623A1 (en) Inflammation and Autoimmune Disorder Treatment using RARa Selective Agonists
JP2001511806A (ja) 神経栄養性スルホンアミド化合物の使用方法
US20110275693A1 (en) Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives
WO2011017201A3 (en) Dp2 antagonist and uses thereof
WO2011159550A3 (en) Lysophosphatidic acid receptor antagonist and uses thereof
US10822301B2 (en) 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase
WO2008077591A3 (en) Pharmaceutical formulation comprising neurokinin antagonist
WO2007012064A2 (en) Prevention and treatment of hearing disorders
CN102066402B (zh) 肽衍生物以及含有肽衍生物的用于促进泪液分泌的组合物
WO2024100452A3 (en) Heterocyclic compounds as sting agonists
WO2023250247A3 (en) R-mdma crystal forms
NO20092764L (no) Isosorbid mononitrat derivater for behandling av okular hypertensjon
US7858655B2 (en) Drug preparation comprising α-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases
US20080261984A1 (en) Use of S,S-Reboxetine in the Treatment of Pain
WO2008102790A1 (ja) 涙液の減少に伴う疾患の予防または治療用医薬組成物
EP1935417A4 (en) COMPOSITION FOR USE IN PREVENTING A HYPOGLYCEMIC STATE
US10434097B1 (en) Methods and compositions for treating hearing disorders
US20160220677A1 (en) Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
CA2805371C (en) Therapeutic agent or prophylactic agent for neuropathic pain
EA201070898A1 (ru) Новое производное хиназолин-2,4-диона и лекарственные композиции на его основе для профилактики и лечения заболевания, обусловленного поражением черепно-мозгового нерва
NZ605516A (en) Sustained-release therapeutic agent for hypertension and renal dysfunction

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711620

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008711620

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2677582

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008218028

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009500203

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 5383/DELNP/2009

Country of ref document: IN

Ref document number: MX/A/2009/008994

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008218028

Country of ref document: AU

Date of ref document: 20080220

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0807715

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090820